Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Darrel P. Cohen, M.D., Ph.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 9:00 a.m. PT/12:00 p.m. ET.
Related news for (VIRX)
- Viracta Therapeutics Announces Wind Down of Operations
- Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- 24/7 Market News Snapshot 06 November, 2024 – Viracta Therapeutics, Inc. Common Stock (NASDAQ:VIRX)
- Viracta Therapeutics Reports Q2 2024 Financial Results and Provides NAVAL-1 Trial Update